Arterial infusion of recombinant human adenoviral p53 gene in treatment of advanced pancreatic cancer.

Abstract

e14523 Background: There are few treatment options for unresectable advanced pancreatic cancer. Here we report beneficial effects of arterial infusion of recombinant human adenoviral p53 gene (rAdp53) in treatment of the late-stage pancreatic cancer. Methods: Sixteen patients having an average age of 56.8 years old, 11 males and 5 females, with unresectable advanced pancreatic cancer were treated using arterial infusion of rAdp53 at dose of 2-4×1012 viral particles (VP) per 3 days for 4 times. The rAdp53diluted into 10 ml ofsaline solution were slowly injected into arterial branches supplying the tumor. Results: Among 16 patients, 56.3% (9/16) achieved a partial response. Overall one year survival rate was 62.5%. Jaundice of 7 in 10 patients was reduced. The ascites of 8 in11 cases was absorbed. General symptoms associated with the late-stage pancreatic cancer were relieved in 81.3% (13/16) of cases. There were no significant side effects or complications observed except for transient fever. Conclusions: The treatment of arterial infusion of rAdp53 showed the beneficiary effects of both safety and efficacy and is a treatment option for unresectable advanced pancreatic cancer.